

DHG

healthcare

CAPABILITIES >>>



SOLUTIONS >>>



**Revenue Portfolio Design and Care
Transformation: or How I Learned to
Love Bundles**

**HFMA
South Texas Chapter
Austin, Texas**

January 20, 2017

Its Friday so...



This will be low stress...



Goals of Our Session

In this session we will introduce the concept of “Revenue Portfolio Design” and it’s importance in Transformational Strategy Development. We will introduce the concept of “Risk Capability” and we will examine the results of clients currently managing under one or more EPM.



Agenda

- “Risk Capability”
- “Revenue Portfolio Design”
- Overview of Cardiac EPM Bundles
 - Spend By Settings
 - Discharge Trends
 - Readmissions
 - Post Acute Providers
 - Case Mix
- Overview of Other Clinical Episodes
- Next Steps to Analyze Episodic Spend
 - UPDATED Super Bundler data
 - Using other data sources to get more timely claims data (MSSP CLFF Files)



Risk Capability



CORE ELEMENTS

- Enterprise Intelligence
- Revenue Transformation
- Clinical Enterprise Maturity



FOUNDATIONAL CATALYSTS

- Innovation Acceleration
- Clinical Assets
- New Infrastructure
- Population Health
- Scenario Planning & Dynamic Financial Modeling
- Leadership & Culture
- Governance

THE RISK CAPABLE ORGANIZATION

Our clients share the common challenge of successfully navigating the unprecedented transition associated with the journey to higher quality at lower cost. The Risk Capable organization is proactively positioned to responsibly plan and confidently respond to the demands of that journey.

CORE ELEMENTS

FOUNDATIONAL CATALYST

RISK CAPABLE FUTURE STATE



+



=



“Why the Need for Risk Capability:
An Industry in Transformation”





Some Truths


- The market is transforming rapidly and at an ever accelerating pace.
- This transformation, while real, is local market specific.
- The ability to effectively manage population health is fundamental to success under Alternative Payment Models.
- It is prudent to initiate significant planning efforts for APM/PHM, including building related supporting infrastructure, before the market compels it.
- The transition to APMs requires a measured and parallel transformation of clinical processes.



Some Truths

- There is increased institutional value when organizations explicitly create critical infrastructure or “risk capability”, to confidently and responsibly accept risk based payment contracts.
- There may be no better opportunity to achieve risk capability than at the present, before the shift to non fee for service payment models require it.
- New payment models and new models of care will require a fresh look at governance.
- Change leadership and pace of change is crucial.

Some People Don't Agree



“Risk Capability and Revenue Transformation”






Alphabet Soup Of Alternative Payment Models






Connecting the APM Dots – Each Program Impacts the Other






Managing Enterprise Risk Under APMs

Future State Design Must Embrace the Full Continuum Care Model





Pulling it all Together: Value Based Future



“Revenue Portfolio Design”





Risk Capability



CORE ELEMENTS

- Enterprise Intelligence
- Revenue Transformation
- Clinical Enterprise Maturity



FOUNDATIONAL CATALYSTS

- Innovation Acceleration
- Clinical Assets
- New Infrastructure
- Population Health
- Scenario Planning & Dynamic Financial Modeling
- Leadership & Culture
- Governance

THE RISK CAPABLE ORGANIZATION

Our clients share the common challenge of successfully navigating the unprecedented transition associated with the journey to higher quality at lower cost. The Risk Capable organization is proactively positioned to responsibly plan and confidently respond to the demands of that journey.

CORE ELEMENTS

FOUNDATIONAL CATALYST

RISK CAPABLE FUTURE STATE



+




=





Risk Capable: Revenue Transformation

Managed **Revenue Transformation** emphasizes the need for a “next-gen” revenue management platform focused on a portfolio perspective, reimbursement across multiple revenue models, and aligned model funds distribution.






Future State Revenue Portfolio

- Continued transition from traditional fee-for-service to APMs requires providers to redesign their revenue portfolio to effectively manage net revenue across an increasingly complex portfolio of models and payment methods
- Healthcare leaders must take a proactive approach in the development and design of their revenue portfolios



Revenue Portfolio Design -- Think Investment Portfolio




Difficult to predict the future






“Revenue Portfolio Design”

Current State



Future State??





Revenue Portfolio Design Factors and Drivers

Each of the following factors have a significant impact on an organization's revenue portfolio design.

Networks

Across the continuum, considering ACOs and CINs

Contracts

Managed care and direct employer opportunities

Governance Capability and Function

Proactively managing design and execution risk

Clinical Quality

Impact on revenue at risk, clinical variability

Data Management and Governance

Aggregation, reporting and usage

Clinical Documentation

Program maturity, impact on revenue at risk

Physician Alignment

Clinical excellence, care coordination and reporting

Post-Acute Strategy

Care transition program, network breadth, performance management and reporting




“Episodic Payment Models”





EPMs by Geography





Episodic Programs

| | Bundle Holder | Duration of Episode | Mandatory/ Voluntary | Financial Risk |
|--------------------------------|-------------------------------|---------------------|-------------------------|--------------------------------|
| BPCI Model 2 | Hospital, PGP | 30-60-90 days | Voluntary | 2-3% Discount |
| BPCI Model 3 | Post-Acute Care Provider, PGP | 30-60-90 days | Voluntary | 3% Discount |
| CJR / SHFFT | Acute Hospital | 90 days | Mandatory | 1.5-3% Discount |
| Oncology Care Model | PGP | 6 months | Voluntary | PMPM Payment; 2.75-4% Discount |
| Cardiac EPM (incl. AMI & CABG) | Acute Hospital | 90 days | Mandatory (Proposed) | 1.5%-3% Discount |

Common Across All Models:

- Encourage and increase care coordination
- Reduce excessive care/spending while maintaining high quality
- Align incentives of providers with achieving better outcomes





Increased Complexity: Target Prices

Bundled Payment for Care Improvement (BPCI)

| | |
|----------------|----------------|
| DRG 469 | Target Price 1 |
| DRG 470 | Target Price 2 |

Comprehensive Joint Replacement (CJR)

| | With Fracture | Without Fracture |
|----------------|----------------------|-------------------------|
| DRG 469 | Target Price 1 | Target Price 2 |
| DRG 470 | Target Price 3 | Target Price 4 |

EPM Cardiac Bundles

50+ Different
Target Prices!

Oncology Care Model

Episode Specific based on
multiple co-variate inputs to
a prediction model



EPM Final Rule



FEDERAL REGISTER

Public Inspection :: Tomorrow's Documents Today

Public Inspection :: Rule

Medicare Program: Advancing Care Coordination through Episode Payment Models; Cardiac Rehabilitation Incentive Payment Model; Changes to the Comprehensive Care for Joint Replacement Model

An unpublished Rule by the Centers for Medicare & Medicaid Services on 01/03/2017

Stay Tuned!

...Building on the BPCI initiative, the [CMS] Innovation Center intends to implement a new voluntary bundled payment model for CY 2018 where the model(s) would be designed to meet the criteria to be an Advanced APM [for APM qualification in MACRA.]


(p.147 of EPM final rule)





An Approach To Using Data

A standardized method of transforming raw claims data into meaningful analysis that helps to drive strategic initiatives.



“Cardiac EPMS”





EPM Spreadsheet


| Latitude | Longitude | CBSA Code | CBSA | Definitive ID |
|-----------|------------|-----------|--|---------------|
| 32.889091 | -97.15114 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 764509 |
| 32.928464 | -97.25466 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 764506 |
| 32.596779 | -97.144867 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 764510 |
| 33.012202 | -96.624275 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 764507 |
| 32.729731 | -97.345167 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 841709 |
| 32.729548 | -97.345547 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 553314 |
| 32.79017 | -96.780442 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 553312 |
| 30.27092 | -97.795894 | 12420 | 12420 - Austin-Round Rock TX | 4161 |
| 33.112438 | -96.801709 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 575751 |
| 32.963287 | -96.745163 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 858508 |
| 32.781445 | -97.419798 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 840511 |
| 33.161295 | -96.637089 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 840622 |
| 32.975365 | -96.72738 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 841697 |
| 30.523273 | -97.81995 | 12420 | 12420 - Austin-Round Rock TX | 551505 |
| 32.956969 | -97.14587 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 579944 |
| 30.331676 | -97.970377 | 12420 | 12420 - Austin-Round Rock TX | 542250 |
| 30.563087 | -97.684849 | 12420 | 12420 - Austin-Round Rock TX | 4192 |
| 32.897235 | -97.312839 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 583173 |
| 33.03158 | -96.854109 | 19100 | 19100 - Dallas-Fort Worth-Arlington TX | 575808 |




The Data



Dilbert.com @ScottAdamsSays



12-7-15 © 2015 Scott Adams, Inc. /Dist. by Universal Uclick



- DILBERT © 2015 Scott Adams. Used By permission of ANDREWS MCMEEL SYNDICATION. All rights reserved.



About the Data

Medicare 100% LDS files for 2012 through 2015 to construct EPM episodes beginning on or after October 1, 2012 and on or before September 30, 2015(Federal Fiscal 2013-2015, 3 Years) – Part B imputed from 5% sample of beneficiaries

- Identify eligible hospitals for EPM models
- Identify potential anchor hospital stays
 - Criteria for initiating an EPM episode
- Beneficiary exclusions
 - Beneficiary is not in Part A and B during the episode period
 - Beneficiary is enrolled in MA plan during the episode period
 - Beneficiary is ESRD as main reason for entitlement
 - Medicare is secondary payer anytime during episode period
 - Patient dies during anchor hospital stay
- Handling of overlapping episodes
 - If overlapping readmission is included readmission for current EPM model, continue original episode, if overlapping readmission is excluded and could trigger another EPM model, cancel the first episode and begin new episode.
- Special handling of transfer cases for AMI and CABG
 - If transferring hospital DRG is AMI, PCI or CABG and receiving hospital DRG is AMI, PCI (with or without AMI Dx) or CABG:
 - Transferring hospital is anchor, model is determined by the DRG of the transferring hospital, price is determined by DRG from transferring or receiving hospital with the highest relative weight
 - If transferring hospital DRG is AMI, PCI or CABG and receiving hospital DRG is not AMI, PCI or CABG: Episode is cancelled




About the Data

- Constructing episodes
 - Anchor hospital period
 - Acute hospital stay – Includes operating, capital and outlier payments. Excludes DSH, IME, new technology, value based purchasing, readmission reduction penalties
 - Post-discharge period
 - Acute hospital readmissions – exclusion lists applied
 - HHA, SNF, LTCH, IRF, Hospice
 - Hospital Outpatient, Part-B, DME – Part B exclusion lists applied
- Calculating Standardized Episode Spending
 - remove effects of wage index and special payment adjustments
- Trending Episode Spending
 - Trend forward the earlier 2 years of baseline data (FFY 2012 and 2013) to the most recent baseline data year (FFY 2014) by Model
- Apply High Episode Payment Winsorization
 - Calculate high episode payment thresholds by EPM Model
 - Cap (winsorize) high cost episodes at these thresholds



Spend By Setting and Model



- Anchor Hospitalization
- Anchor Part B Physician
- SNF
- Outpatient
- IRF
- Post Anchor Part B Physician
- CABG Readmission (AMI Episodes)
- Hospice
- Transfers (Chained Hospitalizations)
- Anchor Part B DME
- Readmissions (excl CABG in AMI)
- HHA
- LTCH
- Post Anchor Part B DME
- Other IP

Key Takeaways:

- CABG & PCI have a larger portion of their spend during the anchor period than AMI. For this reason, AMI may have the most “impactable” spend after the discharge from the acute anchor stay



Spend By Setting and Model

| Spend By Setting & Period | Sample Hospital | | | | 5 South Atlantic | | | | National | | | |
|--------------------------------------|-----------------|-----------------|-----------------|-----------------|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | AMI | PCI | CABG | Total | AMI | PCI | CABG | Total | AMI | PCI | CABG | Total |
| Epi Count per Hsp | 279 | 370 | 391 | 1040 | 134 | 118 | 86 | 327 | 115 | 101 | 74 | 275 |
| Anchor Hospitalization | \$7,873 | \$13,367 | \$29,393 | \$17,918 | \$7,668 | \$13,177 | \$28,256 | \$14,501 | \$7,751 | \$13,162 | \$28,400 | \$14,487 |
| Transfers (Chained Hospitalizations) | \$0 | \$31 | \$0 | \$11 | \$159 | \$576 | \$1,316 | \$581 | \$159 | \$612 | \$1,168 | \$555 |
| Anchor Part B Physician | \$1,483 | \$1,982 | \$5,755 | \$3,267 | \$1,484 | \$2,008 | \$5,780 | \$2,688 | \$1,417 | \$1,905 | \$5,649 | \$2,579 |
| Anchor Part B DME | \$29 | \$61 | \$31 | \$41 | \$29 | \$63 | \$33 | \$42 | \$25 | \$38 | \$29 | \$30 |
| Total Anchor Period | \$9,664 | \$15,811 | \$35,570 | \$22,277 | \$9,474 | \$15,942 | \$35,471 | \$18,139 | \$9,467 | \$15,818 | \$35,320 | \$17,926 |
| % of Episode Spend | 40.3% | 67.7% | 73.8% | 67.8% | 39.4% | 64.5% | 75.3% | 60.9% | 38.7% | 63.8% | 74.8% | 59.9% |
| SNF | \$2,334 | \$634 | \$1,178 | \$1,295 | \$3,762 | \$1,233 | \$2,232 | \$2,504 | \$4,110 | \$1,331 | \$2,346 | \$2,720 |
| Readmissions (excl CABG in AMI) | \$4,092 | \$2,841 | \$3,361 | \$3,372 | \$4,571 | \$2,864 | \$2,552 | \$3,488 | \$4,576 | \$2,834 | \$2,558 | \$3,491 |
| Outpatient | \$1,228 | \$1,306 | \$1,033 | \$1,183 | \$1,004 | \$1,312 | \$1,144 | \$1,146 | \$1,071 | \$1,524 | \$1,309 | \$1,286 |
| HHA | \$974 | \$416 | \$1,598 | \$1,010 | \$1,013 | \$588 | \$1,711 | \$1,028 | \$950 | \$550 | \$1,553 | \$951 |
| IRF | \$1,056 | \$418 | \$2,942 | \$1,538 | \$539 | \$351 | \$1,731 | \$755 | \$520 | \$355 | \$1,689 | \$735 |
| LTCH | \$761 | \$195 | \$727 | \$547 | \$301 | \$149 | \$374 | \$264 | \$478 | \$214 | \$578 | \$409 |
| Post Anchor Part B Physician | \$2,161 | \$1,644 | \$1,923 | \$1,887 | \$2,117 | \$1,722 | \$1,751 | \$1,890 | \$2,092 | \$1,648 | \$1,675 | \$1,838 |
| Post Anchor Part B DME | \$234 | \$241 | \$217 | \$230 | \$205 | \$232 | \$201 | \$214 | \$176 | \$205 | \$174 | \$186 |
| CABG Readmission (AMI Episodes) | \$644 | \$0 | \$0 | \$173 | \$420 | \$278 | \$0 | \$270 | \$433 | \$255 | N/A | \$270 |
| Other IP | \$457 | \$30 | \$4 | \$135 | \$101 | \$50 | \$32 | \$66 | \$161 | \$83 | \$63 | \$110 |
| Hospice | \$680 | \$172 | \$30 | \$255 | \$702 | \$114 | \$17 | \$332 | \$564 | \$82 | \$14 | \$266 |
| Total Post Acute Period | \$14,621 | \$7,897 | \$13,013 | \$11,625 | \$14,735 | \$8,893 | \$11,745 | \$11,957 | \$15,131 | \$9,081 | \$11,959 | \$12,262 |
| % of Episode Spend | 60.9% | 33.8% | 27.0% | 35.4% | 61.2% | 36.0% | 24.9% | 40.2% | 61.8% | 36.6% | 25.3% | 41.0% |
| Payment Total | \$24,005 | \$23,338 | \$48,192 | \$32,861 | \$24,074 | \$24,717 | \$47,130 | \$29,769 | \$24,483 | \$24,798 | \$47,205 | \$29,912 |
| Payment Total Trended | \$24,246 | \$24,033 | \$49,151 | \$33,533 | \$24,335 | \$25,507 | \$48,134 | \$30,394 | \$24,749 | \$25,589 | \$48,204 | \$30,534 |
| Payment Total Trended & Winsorized | \$23,238 | \$23,501 | \$47,046 | \$32,283 | \$23,435 | \$24,587 | \$46,851 | \$29,396 | \$23,812 | \$24,664 | \$46,896 | \$29,515 |

Key Takeaways:

- Readmission spend is a potential target for improvement
- CABG Post Anchor Spend is higher than regional and national averages






Key Metrics

| | Sample Hospital | | | | 5 South Atlantic | | | | National | | | |
|----------------------------------|-----------------|----------|-------|----------|------------------|----------|----------|----------|----------|----------|----------|----------|
| | AMI | PCI | CABG | Total | AMI | PCI | CABG | Total | AMI | PCI | CABG | Total |
| Coefficient of Variation | 73.2% | 55.2% | 40.0% | 62.1% | 70.8% | 54.8% | 38.0% | 63.4% | 70.9% | 55.6% | 39.5% | 64.0% |
| % Episodes w Readmit | 33.3% | 22.7% | 26.6% | 27.0% | 34.1% | 23.3% | 21.4% | 27.3% | 34.2% | 22.8% | 21.0% | 27.1% |
| Total Readm Count/Total Episodes | 50.5% | 28.9% | 35.8% | 37.3% | 50.3% | 32.9% | 28.6% | 39.0% | 49.9% | 32.1% | 27.8% | 38.5% |
| Chained % | 0.0% | 0.3% | 0.0% | 0.1% | 2.1% | 4.3% | 4.4% | 3.4% | 2.1% | 4.5% | 3.8% | 3.4% |
| Chained Episode Spend | \$0 | \$22,399 | \$0 | \$22,399 | \$28,538 | \$30,478 | \$54,128 | \$37,160 | \$29,422 | \$31,149 | \$55,907 | \$37,300 |
| Anchor ALOS | 5.1 | 4.0 | 9.3 | 6.3 | 4.8 | 3.8 | 8.8 | 5.4 | 4.7 | 3.7 | 8.6 | 5.3 |

Readmission Rates



Key Takeaways:

- Readmission rates are favorable in AMI & PCI
- Potential for improvement in CABG readmission rates



First Readmission Analysis

| Readmission DRG & Description | % of First Readmissions | Avg. Days from Discharge | % Readmit to Index |
|--|-------------------------|--------------------------|--------------------|
| Congestive heart failure | 12.1% | 25 | 85.3% |
| Percutaneous coronary intervention | 7.8% | 34 | 81.8% |
| Acute myocardial infarction | 5.7% | 21 | 75.0% |
| Renal failure | 5.3% | 22 | 73.3% |
| Chronic obstructive pulmonary disease, bronchitis, asthma | 3.6% | 46 | 70.0% |
| Gastrointestinal hemorrhage | 3.2% | 28 | 44.4% |
| Cardiac arrhythmia | 2.8% | 26 | 50.0% |
| Other respiratory | 2.8% | 32 | 87.5% |
| Esophagitis, gastroenteritis and other digestive disorders | 2.5% | 26 | 85.7% |
| Sepsis | 2.5% | 31 | 71.4% |
| Urinary tract infection | 2.5% | 32 | 57.1% |
| Chest pain | 2.1% | 36 | 66.7% |
| Coronary artery bypass graft | 1.8% | 32 | 100.0% |
| Major cardiovascular procedure | 1.8% | 40 | 100.0% |
| Red blood cell disorders | 1.8% | 34 | 60.0% |
| Medical non-infectious orthopedic | 1.4% | 33 | 50.0% |
| Other vascular surgery | 1.4% | 45 | 75.0% |
| Pacemaker | 1.4% | 69 | 100.0% |

Key Takeaways:

- Top reasons for readmissions are CHF, PCI & AMI
- CHF patients primarily come back to anchor hospital for care while AMI and Renal Failure readmissions may be seen in other acute hospitals
- Average days from discharge indicates most readmissions occur 20+ days from discharge



Discharge Trends




Discharge Trends

| Sample Hospital | | | | |
|-----------------|-------|-------|-------|-------|
| | AMI | PCI | CABG | Total |
| home | 64.5% | 84.1% | 39.4% | 62.0% |
| hha | 14.7% | 7.3% | 39.1% | 21.3% |
| snf | 10.0% | 4.1% | 5.1% | 6.1% |
| irf | 4.3% | 1.4% | 14.6% | 7.1% |
| other | 6.5% | 3.2% | 1.8% | 3.6% |

| 5 South Atlantic | | | | |
|------------------|-------|-------|-------|-------|
| | AMI | PCI | CABG | Total |
| home | 58.6% | 79.5% | 31.3% | 59.5% |
| hha | 15.2% | 10.0% | 40.2% | 19.3% |
| snf | 18.5% | 6.1% | 17.3% | 13.8% |
| irf | 1.9% | 1.3% | 9.4% | 3.5% |
| other | 5.8% | 3.1% | 1.8% | 3.9% |

| National | | | | |
|----------|-------|-------|-------|-------|
| | AMI | PCI | CABG | Total |
| home | 55.8% | 78.6% | 33.6% | 58.6% |
| hha | 15.4% | 10.2% | 37.1% | 18.7% |
| snf | 21.1% | 6.8% | 18.0% | 15.3% |
| irf | 1.8% | 1.3% | 9.2% | 3.4% |
| other | 6.0% | 3.1% | 2.2% | 4.1% |

Discharge Destination (% Episodes)



home hha snf irf other

home hha snf irf other

home hha snf irf other

Key Takeaways:

- High IRF utilization across all model types





Discharge Trends

| Discharge Trends | | Sample Hospital | | | | 5 South Atlantic | | | | National | | | |
|---|-------|-----------------|--------|--------|--------|------------------|--------|--------|--------|----------|--------|--------|--------|
| | | AMI | PCI | CABG | Total | AMI | PCI | CABG | Total | AMI | PCI | CABG | Total |
| % Episodes w/ Readmission by Disch Dest | home | 30.6% | 18.0% | 18.2% | 21.6% | 26.6% | 17.4% | 14.7% | 20.8% | 27.4% | 17.2% | 14.1% | 20.8% |
| | hha | 36.6% | 37.0% | 25.5% | 29.0% | 38.6% | 33.6% | 17.7% | 27.3% | 38.1% | 31.3% | 17.5% | 27.2% |
| | snf | 35.7% | 40.0% | 40.0% | 38.1% | 43.9% | 43.6% | 31.4% | 40.1% | 41.1% | 41.7% | 30.2% | 38.2% |
| | irf | 25.0% | 40.0% | 38.6% | 36.5% | 46.6% | 50.5% | 31.1% | 37.1% | 45.3% | 43.5% | 30.3% | 35.5% |
| | other | 55.6% | 83.3% | 100.0% | 73.0% | 63.0% | 90.0% | 77.3% | 72.2% | 60.3% | 87.1% | 69.3% | 68.7% |
| Episode Spend as % of Target Price | home | 85.2% | 94.0% | 89.9% | 90.4% | 80.1% | 92.3% | 90.9% | 88.0% | 80.1% | 92.1% | 90.7% | 87.9% |
| | hha | 106.9% | 103.9% | 96.7% | 98.5% | 98.9% | 110.1% | 93.1% | 97.3% | 95.6% | 107.9% | 93.1% | 96.3% |
| | snf | 154.2% | 151.3% | 128.6% | 141.5% | 150.4% | 152.3% | 120.2% | 138.4% | 143.3% | 149.9% | 119.0% | 135.1% |
| | irf | 163.4% | 190.9% | 145.6% | 149.5% | 177.6% | 174.2% | 134.0% | 144.7% | 173.5% | 169.6% | 131.7% | 142.2% |
| | other | 131.8% | 161.4% | 127.9% | 139.6% | 134.9% | 148.2% | 137.3% | 139.3% | 136.7% | 153.1% | 143.2% | 142.6% |

Key Takeaways:

- CABG Episodes discharged to SNF & HHA have a high readmission rates compared to Region and National Averages
- PCI Episodes discharged to IRF or SNF have high episodic spend in relation to target price compared to Region and National Averages in the same discharge settings






Case Mix / Coding


AMI DRGS

■ W/ MCC ■ W/ CC ■ Without CC or MCC




CABG DRGS

■ W/ MCC ■ W/ CC ■ Without CC or MCC



PCI DRGS

■ W/ MCC ■ W/ CC ■ Without CC or MCC



Key Takeaways:

- Case Mix contains less DRGs with MCCs than regional and national averages in CABG & PCIs



Estimated 1 Year Financial Impact

| Per Episode | Cardiac Episode Price DRG | | | |
|-----------------------------------|----------------------------------|----------------|------------------|---------------|
| | AMI | PCI | CABG | Cardiac Total |
| <i>Epi Count</i> | 148 | 142 | 168 | |
| <i>Avg Episode Payment</i> | \$25,909 | \$28,670 | \$55,889 | |
| <i>Winsorized Payment</i> | \$24,534 | \$27,055 | \$54,669 | |
| <i>Estimated Target Price</i> | \$23,985 | \$26,210 | \$52,083 | |
| Estimated NPRA per Episode | (\$549) | (\$845) | (\$2,586) | |

| Aggregate | AMI | PCI | CABG | |
|--------------------------------------|-------------------|--------------------|--------------------|--------------------|
| <i>Epi Count</i> | 148 | 142 | 168 | 458 |
| <i>Total Episode Payment</i> | \$3,834,532 | \$4,071,140 | \$9,389,352 | \$17,295,024 |
| <i>Total Winsorized Payment</i> | \$3,631,032 | \$3,841,810 | \$9,184,392 | \$16,657,234 |
| <i>Total Aggregate Target Price</i> | \$3,549,712 | \$3,721,827 | \$8,749,920 | \$16,021,459 |
| Estimated Total Uncapped NPRA | (\$81,320) | (\$119,983) | (\$434,472) | (\$635,775) |
| % Spend of Target | 102.3% | 103.2% | 105.0% | 104.0% |

| | AMI MODEL | CABG MODEL |
|------------------------------------|--------------------|--------------------|
| <i>Stop Gain/Loss</i> | 5.0% | 5.0% |
| <i>Stop Gain/Loss Threshold</i> | \$363,577 | \$437,496 |
| <i>Total Uncapped NPRA</i> | (\$201,303) | (\$434,472) |
| Estimated Total Capped NPRA | (\$201,303) | (\$434,472) |

| Estimated Target Price Components | AMI | PCI | CABG |
|--|----------|----------|----------|
| <i>Hosp TP (Pre Discount)</i> | \$24,820 | \$27,569 | \$54,825 |
| <i>Region TP (Pre Discount)</i> | \$24,539 | \$25,924 | \$51,431 |
| <i>Blended (if min. volume met)</i> | \$24,726 | \$27,021 | \$53,694 |
| <i>Discount</i> | 3.0% | 3.0% | 3.0% |
| <i>Target Price</i> | \$23,985 | \$26,210 | \$52,083 |

*Modeled as if 2015 was a performance year with downside risk



Cardiac Rehab Incentive Model






CR Incentive Overview

“Considering the evidence demonstrating that CR/ICR services improve long-term patient outcomes, we believe that there is a need for improved long-term care management and care coordination for beneficiaries that have had an AMI or a CABG and that incentivizing the use of CR/ICR services is an important component of meeting this need. ”

-EPM Final Rule

HCPCS codes for CR/ICR services in the CR performance year when those CR/ICR services are paid under the OPSS or to supplier reporting place of service code 11 on a PFS claim

| HCPCS Code | Descriptor |
|------------|--|
| 93797 | Physician services for outpatient cardiac rehabilitation; without continuous ECG monitoring (per session) |
| 93798 | Physician services for outpatient cardiac rehabilitation; with continuous ECG monitoring (per session) |
| G0422 | Intensive cardiac rehabilitation; with or without continuous ECG monitoring with exercise, per session |
| G0423 | Intensive cardiac rehabilitation; with or without continuous ECG monitoring; without exercise, per session |





CR Incentive Overview

TABLE 52: CR MSA SELECTION GROUP DEFINITION AND NUMBER OF MSAS TO BE SELECTED.

| CR Selection Group # | # hospitals billing for CR | % of Eligible Medicare FFS patients starting CR | % of patients starting CR completing 25 sessions | # Selection Eligible MSAs | # Cardiac EPM MSAs | # of EPM-CR and FFS-CR MSAs to be selected from group (0.46 x # EPM) |
|----------------------|----------------------------|---|--|---------------------------|--------------------|--|
| 1 | 1 | < 20% | Any | 40 | 4 | 2 |
| 2 | 1 | 20% + | Any | 35 | 16 | 7 |
| 3 | 2 + | < 20% | Any | 67 | 17 | 8 |
| 4 | 2 + | 20-30% | < 60% | 34 | 13 | 6 |
| 5 | 2 + | 20-30% | 60% + | 52 | 19 | 9 |
| 6 | 2 + | 30% + | < 60% | 37 | 15 | 7 |
| 7 | 2 + | 30% + | 60% + | 28 | 14 | 6 |
| Total | | | | 293 | 98 | 45 |

Example Scenarios:

| CR Selection Group # | Hospital | AMI/CAB G Volume | % of Eligible Medicare FFS patients starting CR | % of patients starting CR completing 25 sessions | Incentive Payments from patients completing 25 sessions | Incentive Payments from patients starting but completing <25 sessions (average 11 visits) | Total Incentive Payment |
|----------------------|------------|------------------|---|--|---|---|-------------------------|
| 1 | Hospital A | 50 | 15% | 20% | \$ 4,088 | \$ 1,650 | \$ 5,738 |
| 2 | Hospital B | 75 | 30% | 80% | \$ 49,050 | \$ 1,238 | \$ 50,288 |
| 3 | Hospital C | 100 | 15% | 50% | \$ 20,438 | \$ 2,063 | \$ 22,501 |
| 4 | Hospital D | 125 | 25% | 45% | \$ 38,320 | \$ 4,727 | \$ 43,047 |
| 5 | Hospital E | 150 | 25% | 60% | \$ 61,313 | \$ 4,125 | \$ 65,438 |
| 6 | Hospital F | 175 | 40% | 25% | \$ 47,688 | \$ 14,438 | \$ 62,126 |
| 7 | Hospital G | 200 | 50% | 75% | \$ 204,375 | \$ 6,875 | \$ 211,250 |






CR Incentive Overview

“We set the proposed service utilization benchmark based on evidence from the literature that shows reduced mortality for Medicare beneficiaries that complete at least 12 CR sessions relative to Medicare beneficiaries who complete 1-11 CR sessions.”


- EPM Final Rule

FIGURE 6: CUMULATIVE INCIDENCE OF MORTALITY BY NUMBER OF CARDIAC REHABILITATION SESSIONS ATTENDED



A study by Hammill et al found that over a 4-year follow-up period beneficiaries who completed 12-23 CR sessions had lower mortality compared to beneficiaries who completed 1-11 CR sessions and that beneficiaries who completed 24 or more CR sessions had lower mortality compared to beneficiaries that completed 12-23 sessions.

FIGURE 7: ESTIMATES OF CUMULATIVE MORTALITY RATES FOR PROPENSITY-BASED MATCHED GROUPS OF CR USE



Another study by Suaya et al. showed that over a 5-year period beneficiaries who were hospitalized for coronary conditions or cardiac revascularization procedures and completed 1-24 CR sessions had lower mortality compared to beneficiaries who were probable candidates for CR but completed 0 CR sessions and that beneficiaries who completed 25 or more CR sessions had lower mortality compared to beneficiaries who completed 1-24 CR sessions




“Additional Clinical Episodes”






Identifying Opportunities in Other Clinical Episodes






Winning” at Episodic Payments






Current Episodes Being Tested in BPCI

Episode Frequency





Identifying Opportunities in Other Clinical Episodes



Example: CHF episodes have \$34 million in 90 day episodic spend across the continuum of care, 65% of which occurs after the initial anchor stay

2013-2014 CMS data






Identifying Opportunities in Other Clinical Episodes

Post Acute Util vs Readmissions

- Cardiac Services
- General Medicine / Internal Medicine
- General Surgery
- Neurology
- Oncology / Hematology
- Orthopedics
- Pulmonology
- Spine
- Vascular Services



2013-2014 CMS data





National Percentile by Episode Group

| Episode Group | SAMPLE HOSPITAL | | | | Top Decile Performers | | Bottom Decile Performers | | National | |
|--|-----------------|-------------------|--------------|------------------|-----------------------|--------------|--------------------------|--------------|-------------------|--------------|
| | Epi Count | Average Epi Spend | Readmit Rate | Spend Percentile | Average Epi Spend | Readmit Rate | Average Epi Spend | Readmit Rate | Average Epi Spend | Readmit Rate |
| Percutaneous coronary intervention | 648 | \$ 22,106 | 21.3% | 65.9% | \$ 19,712 | 17.0% | \$ 29,009 | 26.7% | \$ 23,058 | 21.7% |
| Major joint replacement of the lower extremity | 634 | \$ 26,226 | 9.5% | 57.1% | \$ 20,704 | 6.7% | \$ 37,478 | 19.2% | \$ 25,589 | 9.9% |
| Cardiac arrhythmia | 448 | \$ 14,528 | 29.0% | 75.7% | \$ 12,827 | 22.0% | \$ 21,093 | 34.6% | \$ 15,668 | 26.9% |
| Stroke | 406 | \$ 28,641 | 21.7% | 39.9% | \$ 21,347 | 18.9% | \$ 35,317 | 28.3% | \$ 28,089 | 22.3% |
| Chronic obstructive pulmonary disease, bronchitis, asthma | 390 | \$ 15,889 | 32.3% | 58.8% | \$ 13,308 | 24.6% | \$ 20,970 | 33.9% | \$ 16,516 | 30.6% |
| Congestive heart failure | 369 | \$ 20,707 | 39.6% | 70.2% | \$ 17,858 | 30.7% | \$ 28,129 | 44.4% | \$ 22,115 | 37.8% |
| Simple pneumonia and respiratory infections | 358 | \$ 20,238 | 26.5% | 41.0% | \$ 15,615 | 22.0% | \$ 25,774 | 30.4% | \$ 19,976 | 26.4% |
| Sepsis | 278 | \$ 31,586 | 34.2% | 18.0% | \$ 21,198 | 24.1% | \$ 38,914 | 33.7% | \$ 27,244 | 28.3% |
| Coronary artery bypass graft | 244 | \$ 44,120 | 25.0% | 57.9% | \$ 38,195 | 15.3% | \$ 57,624 | 23.6% | \$ 44,907 | 19.3% |
| Urinary tract infection | 242 | \$ 18,252 | 24.4% | 68.9% | \$ 15,142 | 21.9% | \$ 25,858 | 30.7% | \$ 19,973 | 26.4% |
| Renal failure | 235 | \$ 19,817 | 23.8% | 68.5% | \$ 16,725 | 23.3% | \$ 27,389 | 34.7% | \$ 21,318 | 29.2% |
| Pacemaker | 217 | \$ 25,225 | 21.2% | 63.9% | \$ 21,845 | 14.5% | \$ 33,421 | 25.9% | \$ 26,398 | 19.9% |
| Gastrointestinal hemorrhage | 191 | \$ 15,307 | 22.0% | 77.3% | \$ 13,470 | 19.8% | \$ 21,956 | 30.8% | \$ 16,860 | 24.7% |
| Medical non-infectious orthopedic | 183 | \$ 22,470 | 21.3% | 78.5% | \$ 19,582 | 21.7% | \$ 31,599 | 29.6% | \$ 24,956 | 25.3% |
| Spinal fusion (non-cervical) | 183 | \$ 41,525 | 16.4% | 25.5% | \$ 31,867 | 8.6% | \$ 50,929 | 19.0% | \$ 38,454 | 12.5% |
| Esophagitis, gastroenteritis and other digestive disorders | 180 | \$ 14,910 | 25.0% | 39.6% | \$ 11,583 | 19.8% | \$ 18,817 | 30.8% | \$ 14,489 | 24.9% |
| Other respiratory | 172 | \$ 30,996 | 34.3% | 28.8% | \$ 20,370 | 28.6% | \$ 41,111 | 40.2% | \$ 27,794 | 34.3% |
| Hip & femur procedures except major joint | 171 | \$ 37,959 | 24.6% | 73.2% | \$ 32,915 | 17.0% | \$ 48,589 | 25.3% | \$ 40,463 | 21.0% |
| Cervical spinal fusion | 170 | \$ 26,227 | 12.4% | 55.8% | \$ 21,291 | 6.7% | \$ 38,178 | 17.6% | \$ 27,338 | 11.4% |
| Acute myocardial infarction | 164 | \$ 20,878 | 28.7% | 81.9% | \$ 18,289 | 24.8% | \$ 32,782 | 54.4% | \$ 24,316 | 38.5% |
| Other vascular surgery | 160 | \$ 31,493 | 27.5% | 48.1% | \$ 24,307 | 23.6% | \$ 41,755 | 38.6% | \$ 31,313 | 30.8% |
| Cardiac valve | 157 | \$ 56,419 | 31.9% | 55.2% | \$ 48,426 | 20.0% | \$ 72,350 | 32.1% | \$ 56,638 | 24.8% |

Wage index removed and payments have been winsorized when comparing across national providers. Deciles based on Average Episodic Spend





National Percentile by Episode Group

| Episode Group | SAMPLE HOSPITAL | | | | Top Decile Performers | | Bottom Decile Performers | | National | |
|---|-----------------|-------------------|--------------|------------------|-----------------------|--------------|--------------------------|--------------|-------------------|--------------|
| | Epi Count | Average Epi Spend | Readmit Rate | Spend Percentile | Average Epi Spend | Readmit Rate | Average Epi Spend | Readmit Rate | Average Epi Spend | Readmit Rate |
| Nutritional and metabolic disorders | 144 | \$ 15,333 | 24.3% | 78.7% | \$ 13,320 | 20.3% | \$ 23,721 | 32.1% | \$ 17,713 | 25.9% |
| Major cardiovascular procedure | 139 | \$ 36,127 | 27.3% | 57.5% | \$ 29,845 | 16.1% | \$ 48,046 | 32.4% | \$ 37,109 | 23.9% |
| Major bowel procedure | 131 | \$ 35,915 | 27.5% | 32.9% | \$ 26,010 | 18.9% | \$ 45,225 | 29.8% | \$ 33,272 | 23.9% |
| Transient ischemia | 130 | \$ 11,091 | 10.8% | 80.5% | \$ 9,674 | 11.9% | \$ 17,344 | 22.0% | \$ 13,033 | 17.0% |
| Chest pain | 120 | \$ 11,784 | 21.7% | 54.5% | \$ 8,904 | 14.1% | \$ 17,152 | 32.5% | \$ 12,174 | 22.1% |
| Syncope & collapse | 111 | \$ 13,092 | 16.2% | 78.2% | \$ 11,418 | 15.0% | \$ 19,757 | 25.6% | \$ 14,992 | 20.1% |
| Cardiac defibrillator | 103 | \$ 48,129 | 22.3% | 50.7% | \$ 41,293 | 17.8% | \$ 59,531 | 30.3% | \$ 48,381 | 25.0% |
| Diabetes | 97 | \$ 20,568 | 39.2% | 23.1% | \$ 13,693 | 21.5% | \$ 24,721 | 34.9% | \$ 18,532 | 29.2% |
| Cellulitis | 91 | \$ 18,388 | 27.5% | 33.7% | \$ 13,352 | 18.8% | \$ 23,511 | 28.8% | \$ 17,403 | 24.1% |
| Gastrointestinal obstruction | 90 | \$ 16,013 | 18.9% | 28.3% | \$ 10,555 | 16.8% | \$ 19,579 | 31.2% | \$ 14,382 | 23.8% |
| Red blood cell disorders | 89 | \$ 18,213 | 33.7% | 44.9% | \$ 13,759 | 24.0% | \$ 23,723 | 42.3% | \$ 18,097 | 33.8% |
| Medical peripheral vascular disorders | 83 | \$ 20,157 | 32.5% | 50.5% | \$ 15,101 | 20.0% | \$ 27,338 | 36.5% | \$ 20,411 | 28.6% |
| Amputation | 82 | \$ 50,016 | 37.8% | 23.6% | \$ 35,391 | 29.9% | \$ 57,811 | 41.7% | \$ 45,170 | 36.5% |
| Back & neck except spinal fusion | 78 | \$ 25,652 | 19.2% | 7.8% | \$ 13,316 | 7.4% | \$ 26,976 | 18.5% | \$ 18,809 | 12.4% |
| Lower extremity and humerus procedure except hip, foot, femur | 68 | \$ 29,727 | 19.1% | 69.3% | \$ 24,192 | 13.4% | \$ 42,283 | 26.0% | \$ 32,433 | 18.7% |
| Revision of the hip or knee | 67 | \$ 33,994 | 17.9% | 59.8% | \$ 27,579 | 10.6% | \$ 46,269 | 25.4% | \$ 35,477 | 17.0% |
| Atherosclerosis | 43 | \$ 13,660 | 20.9% | 72.5% | \$ 10,762 | 20.5% | \$ 23,034 | 52.6% | \$ 16,269 | 34.5% |
| Pacemaker device replacement or revision | 41 | \$ 25,893 | 24.4% | 55.5% | \$ 19,250 | 13.3% | \$ 37,974 | 32.2% | \$ 26,721 | 24.8% |
| Major joint replacement of the upper extremity | 33 | \$ 25,330 | 12.1% | 26.4% | \$ 18,410 | 4.6% | \$ 30,412 | 10.7% | \$ 22,955 | 7.9% |
| Fractures of the femur and hip or pelvis | 31 | \$ 26,387 | 22.6% | 69.7% | \$ 21,159 | 16.0% | \$ 36,243 | 30.8% | \$ 28,739 | 24.2% |
| Double joint replacement of the lower extremity | 30 | \$ 34,386 | 0.0% | 76.0% | \$ 28,783 | 4.1% | \$ 45,651 | 15.7% | \$ 37,811 | 8.4% |

Wage index removed and payments have been winsorized when comparing across national providers. Deciles based on Average Episodic Spend



“Next Steps”





Next Steps

- Understanding historical data will be crucial to identifying opportunity in future bundling initiatives
 - Episodic model methodologies rely on a historical “baseline” period of data
 - Generally, baseline periods are 2-3 years prior to performance period, which makes understanding 2014-2015 data relevant and important

Mandatory Programs

CJR & EPM

- Currently updating with 2015 data
- Analyses created from SAF LDS files based on episode specs from final or proposed rules
- Ability to Compare to Regional & National Trends
- CMS Data Restrictions (<11)
- Part B claims imputed from 5% sample

Voluntary Programs

Super Bundler

- Currently updating with 2015 data
- Analyses created from SAF LDS files based on episode specs BPCI
- Modeled for Model 2, 90 Day Episodes for all 48 Episode Groups available in the BPCI Program
- Ability to Compare to Regional & National Trends
- CMS Data Restrictions (<11)
- Part B claims imputed from 5% sample




Next Steps

- If more up-to-date data is necessary, monthly ACO claims files could be used to “build” bundles and analyze key metrics and understand utilization

Current Performance/ Custom Data Pulls

ACO CCLF Files

- Monthly CMS transmission for MSSP participants
- Most recent claims files available
- Ability to model for IP initiated episodes or other custom data pulls
- Full Patient/Episode Detail available
- Tableau Enabled Dashboard





CMS Analytics – Critical to Risk Capability

CORE COMPETENCIES

PROGRAM COMPETENCIES

| PERFORMANCE | POST-ACUTE | EPISODIC | PROGRAM SPECIFIC | |
|--------------|-----------------|----------------------------|------------------|------------|
| Readmissions | SNF Performance | EPM Readiness | Mandatory | CJR EPM |
| HACS | Home Health | BPCI Readiness | | Voluntary |
| MACRA | | Episodic Spend & Variation | | |
| VBP/MSPB | | | | |


DHG TOOLS / RESOURCES

| | | | |
|----------------|-----------------------|--|--|
| QNET Analytics | Post-Acute Scorecards | EPM Analytics BPCI Analytics “Super Bundler” | CRJ Quarterly Manager EPM Quarterly Manager BPCI Monthly Manager OCM Quarterly Manager ACO Monthly Manager National Episodic Benchmarks |
|----------------|-----------------------|--|--|





EPM Spend By Setting and Model



- Anchor Hospitalization
- SNF
- HHA
- Post Anchor Part B Physician
- Other IP
- Anchor Part B Physician
- Readmissions (excl CABG in AMI)
- IRF
- Post Anchor Part B DME
- Anchor Part B DME
- Outpatient
- CABG Readmission (AMI Episodes)
- LTCH
- Hospice





EPMs - Estimated 1 Year Financial Impact

| Per Episode | Episode Price DRG | | | |
|-----------------------------------|-------------------|--------------|------------------|------------------|
| | AMI | PCI | CABG | Total |
| Epi Count | 229 | 60 | 64 | 353 |
| Avg Episode Payment | \$23,485 | \$22,927 | \$49,188 | \$28,050 |
| Winsorized Payment | \$23,054 | \$22,480 | \$49,002 | \$27,661 |
| Estimated Target Price | \$21,216 | \$22,757 | \$47,574 | \$26,257 |
| Estimated NPRA per Episode | (\$1,838) | \$277 | (\$1,428) | (\$1,404) |

| Per Episode | CJR ADD |
|-----------------------------------|------------------|
| | SHFFT |
| Epi Count | 100 |
| Avg Episode Payment | \$47,113 |
| Winsorized Payment | \$46,549 |
| Estimated Target Price | \$43,144 |
| Estimated NPRA per Episode | (\$3,405) |

| Aggregate | AMI | PCI | CABG | Total |
|--------------------------------------|--------------------|-----------------|-------------------|--------------------|
| Epi Count | 229 | 60 | 64 | 353 |
| Total Episode Payment | \$5,378,065 | \$1,375,620 | \$3,148,032 | \$14,613,017 |
| Total Winsorized Payment | \$5,279,366 | \$1,348,800 | \$3,136,128 | \$14,419,194 |
| Total Aggregate Target Price | \$4,858,543 | \$1,365,395 | \$3,044,763 | \$13,583,053 |
| Estimated Total Uncapped NPRA | (\$420,823) | \$16,595 | (\$91,365) | (\$836,141) |
| % Spend of Target | 108.7% | 98.8% | 103.0% | 105.3% |

| Aggregate | SHFFT |
|--------------------------------------|--------------------|
| Epi Count | 100 |
| Total Episode Payment | \$4,711,300 |
| Total Winsorized Payment | \$4,654,900 |
| Total Aggregate Target Price | \$4,314,352 |
| Estimated Total Uncapped NPRA | (\$340,548) |
| % Spend of Target | 107.9% |

| | AMI MODEL | CABG MODEL | Total |
|------------------------------------|--------------------|-------------------|--------------------|
| Stop Gain/Loss | 5.0% | 5.0% | |
| Stop Gain/Loss Threshold | \$311,197 | \$152,238 | |
| Total Uncapped NPRA | (\$404,228) | (\$91,365) | |
| Estimated Total Capped NPRA | (\$311,197) | (\$91,365) | (\$402,562) |

| | SHFFT |
|------------------------------------|--------------------|
| Stop Gain/Loss | 5.0% |
| Stop Gain/Loss Threshold | \$215,718 |
| Total Uncapped NPRA | (\$340,548) |
| Estimated Total Capped NPRA | (\$215,718) |


| Estimated Target Price Components | AMI | PCI | CABG | Total |
|-----------------------------------|----------|----------|----------|----------|
| Hosp TP (Pre Discount) | \$20,998 | \$22,992 | \$48,377 | \$26,301 |
| Region TP (Pre Discount) | \$22,952 | \$23,679 | \$48,882 | \$27,777 |
| Blended (if min. volume met) | \$21,649 | \$23,221 | \$48,545 | \$26,793 |
| Discount | 2.0% | 2.0% | 2.0% | 2.0% |
| Target Price | \$21,216 | \$22,757 | \$47,574 | \$26,257 |

| Estimated Target Price Components | SHFFT |
|-----------------------------------|----------|
| Hosp TP (Pre Discount) | \$44,419 |
| Region TP (Pre Discount) | \$43,234 |
| Blended (if min. volume met) | \$44,024 |
| Discount | 2.0% |
| Target Price | \$43,144 |





Total Episodic Payments by Product Line




Source: CMS Public Use Files, 2013-2014 Data Years





Post Acute Utilization vs Readmission Rates





Super Bundler Overview

| Episode Group | Sample Hospital | | | Top Decile Performers | | Bottom Decile Performers | | National | |
|---|-------------------|--------------|------------------|-----------------------|--------------|--------------------------|--------------|-------------------|--------------|
| | Average Epi Spend | Readmit Rate | Spend Percentile | Average Epi Spend | Readmit Rate | Average Epi Spend | Readmit Rate | Average Epi Spend | Readmit Rate |
| Acute myocardial infarction | \$ 18,057 | 21.6% | 95.8% | \$ 18,289 | 24.8% | \$ 32,782 | 54.4% | \$ 24,316 | 38.5% |
| Other respiratory | \$ 20,721 | 31.0% | 94.0% | \$ 20,370 | 28.6% | \$ 41,111 | 40.2% | \$ 27,794 | 34.3% |
| Major bowel procedure | \$ 28,035 | 21.2% | 87.4% | \$ 26,010 | 18.9% | \$ 45,225 | 29.8% | \$ 33,272 | 23.9% |
| Chronic obstructive pulmonary disease, bronchitis, asthma | \$ 14,218 | 25.0% | 87.2% | \$ 13,308 | 24.6% | \$ 20,970 | 33.9% | \$ 16,516 | 30.6% |
| Transient ischemia | \$ 10,772 | 13.5% | 84.1% | \$ 9,674 | 11.9% | 17344.05 | 22.0% | \$ 13,033 | 17.0% |
| Atherosclerosis | \$ 12,520 | 0.0% | 83.9% | \$ 10,762 | 20.5% | \$ 23,034 | 52.6% | \$ 16,269 | 34.5% |
| Gastrointestinal hemorrhage | \$ 15,077 | 20.2% | 81.0% | \$ 13,470 | 19.8% | \$ 21,956 | 30.8% | \$ 16,860 | 24.7% |
| Other vascular surgery | \$ 27,534 | 23.1% | 79.0% | \$ 24,307 | 23.6% | \$ 41,755 | 38.6% | \$ 31,313 | 30.8% |
| Renal failure | \$ 19,002 | 21.6% | 78.7% | \$ 16,725 | 23.3% | \$ 27,389 | 34.7% | \$ 21,318 | 29.2% |
| Cardiac arrhythmia | \$ 14,440 | 24.2% | 77.2% | \$ 12,827 | 22.0% | \$ 21,093 | 34.6% | \$ 15,668 | 26.9% |
| Medical non-infectious orthopedic | \$ 22,805 | 17.6% | 75.2% | \$ 19,582 | 21.7% | \$ 31,599 | 29.6% | \$ 24,956 | 25.3% |
| Congestive heart failure | \$ 20,480 | 36.5% | 73.7% | \$ 17,858 | 30.7% | \$ 28,129 | 44.4% | \$ 22,115 | 37.8% |
| Cardiac defibrillator | \$ 45,863 | 0.0% | 68.1% | \$ 41,293 | 17.8% | \$ 59,531 | 30.3% | \$ 48,381 | 25.0% |
| Nutritional and metabolic disorders | \$ 16,282 | 18.4% | 67.4% | \$ 13,320 | 20.3% | \$ 23,721 | 32.1% | \$ 17,713 | 25.9% |
| Cervical spinal fusion | \$ 25,082 | 13.8% | 65.6% | \$ 21,291 | 6.7% | \$ 38,178 | 17.6% | \$ 27,338 | 11.4% |
| Fractures of the femur and hip or pelvis | \$ 26,919 | 21.3% | 65.1% | \$ 21,159 | 16.0% | \$ 36,243 | 30.8% | \$ 28,739 | 24.2% |
| Simple pneumonia and respiratory infection | \$ 18,780 | 27.1% | 64.3% | \$ 15,615 | 22.0% | 25773.51 | 30.4% | \$ 19,976 | 26.4% |
| Pacemaker | \$ 25,193 | 19.4% | 64.2% | \$ 21,845 | 14.5% | \$ 33,421 | 25.9% | \$ 26,398 | 19.9% |
| Sepsis | \$ 25,701 | 31.9% | 60.9% | \$ 21,198 | 24.1% | 38914.39 | 33.7% | \$ 27,244 | 28.3% |
| Percutaneous coronary intervention | \$ 22,580 | 16.3% | 57.2% | \$ 19,712 | 17.0% | \$ 29,009 | 26.7% | \$ 23,058 | 21.7% |
| Major joint replacement of the lower extremity | \$ 26,392 | 9.8% | 55.5% | \$ 20,704 | 6.7% | \$ 37,478 | 19.2% | \$ 25,589 | 9.9% |
| Cellulitis | \$ 16,948 | 21.6% | 54.6% | \$ 13,352 | 18.8% | \$ 23,511 | 28.8% | \$ 17,403 | 24.1% |
| Amputation | \$ 44,158 | 0.0% | 53.5% | \$ 35,391 | 29.9% | \$ 57,811 | 41.7% | \$ 45,170 | 36.5% |
| Urinary tract infection | \$ 19,612 | 24.0% | 51.7% | \$ 15,142 | 21.9% | 25858.03 | 30.7% | \$ 19,973 | 26.4% |





Concluding Thoughts:

- The shift to Value, which has significant market momentum, is likely to continue regardless of “Repeal and Replace.”
- An organization’s ability to understand their DATA is crucial to success in a Value based world.
- The development of new and different care models, parallel to the adoption of EPMs, is critical to success.
- Accurate and complete Clinical Documentation has never been more important.
- Planning and organizing across the continuum and across all payers are critical success factors.
- Keeping governance engaged and informed is crucial.



Upcoming Events

- We are presenting at the LA HFMA Chapter in Baton Rouge on January 23rd.
- Join us at Lone Star Chapter in Garland on January 26 and 27
- DHG Healthcare will be at the THA Annual Meeting in Austin on January 26 and 27
- DHG Healthcare is a sponsor and presenter at the HFMA National Payment Summit in Dallas on February 8th through the 10th.

DHG

.....
healthcare

Bill Hannah//Principal

DHG Healthcare
Fort Worth, TX
P: 817.276.4122
C: 404.561.0227

Heather Spillman//SR. Manager

DHG Healthcare
Austin, TX
P: 817.276.4122
C: 404.849.7787